国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2008年
12期
2359-2363
,共5页
胼酞嗪%脉络膜%新生血管%人脐静脉内皮细胞%年龄相关性黄斑变性
胼酞嗪%脈絡膜%新生血管%人臍靜脈內皮細胞%年齡相關性黃斑變性
변태진%맥락막%신생혈관%인제정맥내피세포%년령상관성황반변성
hydralazine%choroid%neovascularization%human umbilical vein endothelial cell%age-related macu-lar degeneration
目的:研究胼酞嗪对兔脉络膜血流和激光诱导的鼠脉络膜新生血管及人脐静脉内皮细胞管状结构形成的影响.方法:雌性新西兰白兔左眼眼内压升高至40mmHg后,滴入10g/L胼酞嗪滴眼液,采用彩色微球技术测量眼血流变化.用Nd:YAG激光诱导雄性Brown Norway大鼠至Bruch膜破裂,而后分别予生理盐水或5,10和20g/L胼酞嗪滴眼液点眼,3次/d,连续4wk.采用眼底荧光血管造影和脉络膜平片测量新生血管的面积.此外亦用不同浓度的胼酞嗪作用于培养之人脐静脉内皮细胞并探讨对其管状结构形成的影响.结果:10g/L胼酞嗪滴眼液滴入眼内压为40mmHg的兔眼30,60min后,脉络膜血流明显增加.眼底荧光血管造影和脉络膜平片测量均显示,经过4wk药物治疗,5,10,20g/L胼酞嗪滴眼液均明显抑制了鼠眼CNV的形成.3～30mg/L胼酞嗪对在基质凝胶中培养了48h的人脐静脉内皮细胞的管状结构的形成有抑制作用.结论:胼酞嗪可以抑制体内脉络膜新生血管及体外培养的人脐静脉内皮细胞管状结构的形成,并增强缺血后的兔脉络膜血流.胼酞嗪有望成为治疗年龄相关性黄斑变性的药物.
目的:研究胼酞嗪對兔脈絡膜血流和激光誘導的鼠脈絡膜新生血管及人臍靜脈內皮細胞管狀結構形成的影響.方法:雌性新西蘭白兔左眼眼內壓升高至40mmHg後,滴入10g/L胼酞嗪滴眼液,採用綵色微毬技術測量眼血流變化.用Nd:YAG激光誘導雄性Brown Norway大鼠至Bruch膜破裂,而後分彆予生理鹽水或5,10和20g/L胼酞嗪滴眼液點眼,3次/d,連續4wk.採用眼底熒光血管造影和脈絡膜平片測量新生血管的麵積.此外亦用不同濃度的胼酞嗪作用于培養之人臍靜脈內皮細胞併探討對其管狀結構形成的影響.結果:10g/L胼酞嗪滴眼液滴入眼內壓為40mmHg的兔眼30,60min後,脈絡膜血流明顯增加.眼底熒光血管造影和脈絡膜平片測量均顯示,經過4wk藥物治療,5,10,20g/L胼酞嗪滴眼液均明顯抑製瞭鼠眼CNV的形成.3～30mg/L胼酞嗪對在基質凝膠中培養瞭48h的人臍靜脈內皮細胞的管狀結構的形成有抑製作用.結論:胼酞嗪可以抑製體內脈絡膜新生血管及體外培養的人臍靜脈內皮細胞管狀結構的形成,併增彊缺血後的兔脈絡膜血流.胼酞嗪有望成為治療年齡相關性黃斑變性的藥物.
목적:연구변태진대토맥락막혈류화격광유도적서맥락막신생혈관급인제정맥내피세포관상결구형성적영향.방법:자성신서란백토좌안안내압승고지40mmHg후,적입10g/L변태진적안액,채용채색미구기술측량안혈류변화.용Nd:YAG격광유도웅성Brown Norway대서지Bruch막파렬,이후분별여생리염수혹5,10화20g/L변태진적안액점안,3차/d,련속4wk.채용안저형광혈관조영화맥락막평편측량신생혈관적면적.차외역용불동농도적변태진작용우배양지인제정맥내피세포병탐토대기관상결구형성적영향.결과:10g/L변태진적안액적입안내압위40mmHg적토안30,60min후,맥락막혈류명현증가.안저형광혈관조영화맥락막평편측량균현시,경과4wk약물치료,5,10,20g/L변태진적안액균명현억제료서안CNV적형성.3～30mg/L변태진대재기질응효중배양료48h적인제정맥내피세포적관상결구적형성유억제작용.결론:변태진가이억제체내맥락막신생혈관급체외배양적인제정맥내피세포관상결구적형성,병증강결혈후적토맥락막혈류.변태진유망성위치료년령상관성황반변성적약물.
·AIM: To investigate the effect of hydralazine on choroidal blood flow in rabbits and laser-induced choroidal neovascularization (CNV) in rats and the effect of hydralazine on tube formation of human umbilical vein endothelial cells (HUVEC).used with raised intraocular pressure (IOP) of the left eye to 40mmHg.Hydralazine (10g/L) eye drops were instilled and ocular blood flow was measured with colored microspheres technique. Male Brown Norway rats were treated with Nd: YAG laser to break Bruch's membrane. Hydralazine (5, 10, 20g/L) eye drops or saline alone was instilled three times a day for 4 weeks after laser treatment. Fluorescein angiography (FA) and choroidal flat mount were used to measure the area of CNV. Tube formation of HUVEC was studied at different concen-trations of hydralazine.hydralazine eye drops enhanced the choroidal blood flow significantly at 30 and 60 minutes after drug instillation. After 4 week of drug treatment, 5, 10 and 20g/L hydralazine eye drops all reduced the CNV formation dramatically measured by fluorescein angiography and choroidal flat mount. When HUVEC was cultured on matrix gel for 48 hours, hydralazine at 3-30mg/L preven-ted the tube formation.vivo and HUVEC tube formation in vitro, and enhanced rabbits' choroidal blood flow after ischemia. It is hoped that hydralazine could be used to treat age-related ma-cular degeneration in the future.
